Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
February 07 2018 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced that
Patrick J. McEnany, Chief Executive Officer, and Steven Miller,
Ph.D., Chief Operating Officer and Chief Scientific Officer, will
participate in the following conferences:
Conference:
20th Annual BIO CEO & Investor
Conference
Date:
February 12,
2018
Presentation Time:
3:30 PM
EST
Conference:
SunTrust Robinson Humphrey 4th Annual Orphan Drug
Day
Date:
February 13,
2018
The presentation materials for the BIO CEO &
Investor conference will be posted at www.catalystpharma.com in the
Investor section under Events and Presentations.
About Catalyst
PharmaceuticalsCatalyst Pharmaceuticals is a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS),
MuSK antibody positive myasthenia gravis, and infantile spasms.
Firdapse® has received Breakthrough Therapy Designation from the
U.S. Food and Drug Administration (FDA) for the treatment of LEMS
and Orphan Drug Designation for LEMS, CMS and myasthenia gravis.
Firdapse is the first and only approved drug in Europe for
symptomatic treatment in adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms. CPP-115 has been granted U.S. Orphan
Drug Designation for the treatment of infantile spasms by the FDA
and has been granted E.U. Orphan Medicinal Product Designation for
the treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking StatementsThis
press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including
those factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2016 and its other filings with the U.S.
Securities and Exchange Commission (SEC), could adversely
affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website or
may be obtained upon request from Catalyst. Catalyst does not
undertake any obligation to update the information contained
herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024